AB Biosciences receives a new patent from USPTO

Boston, October 31, 2023 – Ab Biosciences, Inc., a biotechnology company developing biologics for chronic inflammatory and autoimmune diseases, today announced that it has received another new patent from the United States Patent and Trademark Office (USPTO, US11,801,286), entitled, “Recombinant intravenous immunoglobulin (RIVIG) compositions and methods for their production and use.”